Maravai Lifesciences Holdings (MRVI) AI Stock Analysis

• Market Cap: $595.90M
• Dividend Yield: N/A
• Average Volume (3M): 1.69M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.71
• Revenue Growth: -11.76%
• EPS Growth: -15.82%
• Country: US
• Employees: 570
• Sector: Healthcare
• Sector Strength: 38
• Industry: Biotechnology
• EPS (TTM): -0.08
• Shares Outstanding: 143,975,430
• 10 Day Avg. Volume: 1,281,614
• 30 Day Avg. Volume: 1,688,067
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: 0.99
• Enterprise Value/Revenue: 2.43
• Enterprise Value/Gross Profit: 6.52
• Enterprise Value/Ebitda: -2.82
• 1Y Price Target: $4.60
• Price Target Upside: 96.58% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 7

• Rating: 49 Neutral
• Price Target: $2.50 ▲(6.84% Upside)

Maravai Lifesciences Holdings faces significant financial challenges with declining revenue and profitability issues. The stock's valuation is strained by a negative P/E ratio. Although recent earnings exceeded expectations, ongoing profitability concerns and geopolitical risks persist. New leadership may provide strategic growth potential, but immediate financial stability is crucial.

Positive Factors

Acquisition Speculation

There is speculation about a potential acquisition of Maravai, which could lead to increased investor interest and potential premium offers.

Leadership and Strategic Vision

Raj Asarpota's extensive experience in leading global acquisitions and driving operational efficiencies is aligned with the company's focus on financial discipline.

Leadership Collaboration

The new CFO, Rajesh Asarpota, and CEO, Bernd Brust, have previously worked together at Life Technologies and Cole-Parmer, suggesting a strong working relationship and potential for effective collaboration.

Negative Factors

COVID Revenue Impact

The company is facing a $66 million headwind in 2025 due to the impact of COVID revenues rolling off its P&L statement.

Financial Guidance Uncertainty

The company has not updated or reaffirmed its financial guidance, indicating potential uncertainty in its financial outlook.

Non-COVID Business Decline

Maravai's non-COVID business has declined year-over-year for nine consecutive quarters, indicating persistent challenges in its key end-markets.

Maravai Lifesciences Holdings Business Overview & Revenue Model

Company Description

Maravai Lifesciences Holdings (MRVI) is a leading provider of life science reagents and services to researchers and biotech companies. The company operates in sectors such as biopharmaceutical development and manufacturing, diagnostics, and genomics. Its core products include nucleic acid production, biologics safety testing, and protein detection products, which support the development of new drugs, diagnostics, and therapeutics.

How the Company Makes Money

Maravai Lifesciences Holdings makes money primarily through the sale of its life science products and services. The company generates revenue by providing high-quality reagents and services that are critical in the development and manufacturing processes of biopharmaceuticals and diagnostics. Key revenue streams include nucleic acid products, which are essential for mRNA-based therapies and vaccines, biologics safety testing for ensuring the safety and efficacy of drugs, and protein detection products used in research and development. Significant partnerships with biotech firms and research institutions also contribute to its earnings by expanding its market reach and customer base.

Maravai Lifesciences Holdings Financial Statement Overview

Summary

Maravai Lifesciences faces significant financial challenges with declining revenue and profitability, leading to negative margins and cash flow issues. Although leverage is low, reduced shareholder equity and assets signal potential risks.

Income Statement

The income statement reveals significant challenges, with the company experiencing negative EBIT and net income in the TTM period. Revenue has declined from the previous year, highlighting a concerning trend. Margins, including gross profit and EBITDA, have deteriorated, indicating profitability issues.

Balance Sheet

The balance sheet shows a moderate financial position. The debt-to-equity ratio is low due to reduced total debt, suggesting manageable leverage. However, the equity ratio has decreased, reflecting reduced shareholder equity. The decline in total assets and equity over time is a concern.

Cash Flow

Cash flow analysis indicates pressure, with a negative free cash flow in the TTM period. The operating cash flow to net income ratio is positive, but both operating and free cash flows have declined, reflecting cash management challenges. The company needs to enhance cash generation strategies.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	259.19M	288.94M	883.00M	799.24M	284.10M
Gross Profit	108.31M	140.20M	714.04M	658.68M	204.45M
EBITDA	-156.92M	712.41M	609.99M	585.78M	138.27M
Net Income	-144.85M	-119.03M	490.66M	469.25M	76.89M
Balance Sheet
Total Assets	1.01B	1.49B	2.28B	1.92B	1.27B
Cash, Cash Equivalents and Short-Term Investments	322.40M	574.96M	632.14M	551.27M	236.18M
Total Debt	376.69M	610.97M	585.26M	534.31M	590.78M
Total Liabilities	431.04M	697.57M	1.38B	1.37B	1.12B
Stockholders Equity	325.29M	416.75M	545.22M	315.50M	88.51M
Cash Flow
Free Cash Flow	-22.19M	60.67M	518.89M	353.72M	126.78M
Operating Cash Flow	7.46M	126.22M	535.98M	368.57M	152.19M
Investing Cash Flow	-24.32M	-122.31M	-267.61M	105.66M	6.07M
Financing Cash Flow	-234.47M	-61.09M	-187.50M	-159.05M	53.21M

Maravai Lifesciences Holdings Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 2.34
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MRVI, the sentiment is Negative. The current price of 2.34 is below the 20-day moving average (MA) of 2.54, below the 50-day MA of 2.39, and below the 200-day MA of 3.78, indicating a bearish trend. The MACD of -0.03 indicates Positive momentum. The RSI at 44.59 is Neutral, neither overbought nor oversold. The STOCH value of 13.46 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for MRVI.

Maravai Lifesciences Holdings Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PHAR	70 Outperform	$840.36M	―	-3.40%	―	22.68%	42.45%
IMNM	52 Neutral	$944.08M	―	-69.21%	―	-13.76%	57.73%
Sector *	50 Neutral	AU$2.60B	3.65	-58.14%	2.69%	36.37%	13.78%
MRVI	49 Neutral	$595.90M	―	-45.75%	―	-11.76%	-15.82%
BCAX	48 Neutral	$619.53M	―	34.94%	―	―	―
LENZ	46 Neutral	$869.35M	―	-26.25%	―	―	68.93%
COGT	37 Underperform	$1.86B	―	-107.55%	―	―	-2.53%

Maravai Lifesciences Holdings Corporate Events

Maravai Lifesciences Appoints New CFO Rajesh Asarpota

On June 22, 2025, Maravai LifeSciences announced the appointment of Rajesh Asarpota as Chief Financial Officer, effective June 30, 2025, succeeding Kevin Herde. Mr. Asarpota, with extensive experience in finance and strategic growth in the life sciences and medical device sectors, will lead Maravai’s financial and strategic initiatives, supporting its focus on nucleic acid technologies and bioprocess impurity analytics. This transition aims to strengthen Maravai’s leadership team and drive long-term value creation for stakeholders.

The most recent analyst rating on (MRVI) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Maravai Lifesciences Holdings stock, see the MRVI Stock Forecast page.

Maravai Lifesciences Appoints Bernd Brust as New CEO

On June 8, 2025, Maravai LifeSciences Holdings appointed Bernd Brust as the new CEO and member of the Board, succeeding William E. Martin, III. This leadership transition aims to enhance innovation and financial performance, with Brust bringing over 30 years of experience in the life sciences industry. The company is poised for long-term success with a strong financial foundation and a commitment to expanding its market leadership in mRNA and bioprocess impurity detection. Maravai plans to continue delivering innovative solutions to researchers and biotech innovators globally.

The most recent analyst rating on (MRVI) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Maravai Lifesciences Holdings stock, see the MRVI Stock Forecast page.

Maravai Lifesciences Holds Annual Shareholders Meeting

On May 22, 2025, Maravai LifeSciences Holdings, Inc. conducted its Annual Meeting of Shareholders. During the meeting, shareholders elected directors for three-year terms, ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for 2025, and approved the compensation of the company’s named executive officers on a non-binding advisory basis.

The most recent analyst rating on (MRVI) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Maravai Lifesciences Holdings stock, see the MRVI Stock Forecast page.